Cancer of the nasopharynx

被引：47

作者：

Licitra, L ^{[1
]}

Bernier, J

Cvitkovic, E

Grandi, C

Spinazzé, S

Bruzzi, P

Gatta, G

Molinari, R

机构：

[1] START Project, Milan, Italy

[2] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy

[3] Inst So Switzerland, Bellinzona, Switzerland

[4] CAC Cvitkovic & Associes Consultants SA, Le Kremlin Bicetre, France

[5] Gen Hosp Santa Chiara, Trenton, NJ USA

[6] Ist Nazl Ric Canc, I-16132 Genoa, Italy

[7] Ist Ortoped Galeazzi, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2003年 / 45卷 / 02期

关键词：

nasopharynx; chemotherapy; radiotherapy;

D O I：

10.1016/S1040-8428(01)00210-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal cancer (NPC) is quite rare throughout Europe, accounting for an annual incidence rate below I per 100.000, whereas the highest risk area is South East Asia. A predominant occurrence in males is to be noted. NPC is an etiologically multifactorial disease, most probably involving viral, genetic and environmental factors. Carcinomas of the nasopharynx can be divided into two major histotypes: keratinizing squamous cell carcinomas (WHO-type 1) and non-keratinizing carcinomas (WHO-type 2). The histological type is a prognostic factor and it has a clear impact on the outcome of treatment. Standard therapeutic option for early stages of NPC is radiation, while an integration of radiation therapy and chemotherapy is indicated in more advanced stages. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：199 / 213

页数：15

共 120 条

[1] DISTANT METASTASES OF NASOPHARYNGEAL CARCINOMA - A STUDY OF 256 MALE-PATIENTS [J].